Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy
| Status: | Completed |
|---|---|
| Conditions: | Skin Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/21/2018 |
| Start Date: | June 23, 2015 |
| End Date: | December 28, 2017 |
Projecting Survival for Patients Treated With First-Line Ipilimumab-Nivolumab Combination Therapy Using a Prognostic Model and Cost Per Responder Model of Ipilimumab-Nivolumab Combination Therapy
This study will review published trial literature and documents for Overall Survival (OS) to
evaluate the association between the hazard of death and each baseline variable.
evaluate the association between the hazard of death and each baseline variable.
Inclusion Criteria:
- Diagnosis of melanoma
Exclusion Criteria:
- Age less than 18 years old
We found this trial at
1
site
Click here to add this to my saved trials
